{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:24Z","timestamp":1786986864382,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008476","name":"University of California, Irvine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T15:13:28Z","timestamp":1768144408000},"page":"e569-e576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Stem Cell Mobilization with Chemotherapy Versus G-CSF Alone for Multiple Myeloma Patients with Suboptimal Response Before Autologous Stem Cell Transplant"],"prefix":"10.1016","volume":"26","author":[{"given":"Piyatida","family":"Chumnumsiriwath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Bellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh-Ha","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2078-7254","authenticated-orcid":false,"given":"Christina","family":"Golly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8597-3271","authenticated-orcid":false,"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyanuch","family":"Kongtim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.01.004_bib0001","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.01.004_bib0002","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.01.004_bib0003","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.01.004_bib0004","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.01.004_bib0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bbmt.2018.09.023","article-title":"Increased efficacy of stem cell chemomobilization with intermediate-dose cytarabine plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone in patients with multiple myeloma: results of a randomized trial","volume":"25","author":"Czerw","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.01.004_bib0006","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-020-04376-w","article-title":"Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis","volume":"100","author":"Wang","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.01.004_bib0007","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/jha2.702","article-title":"A comparison of peripheral blood stem cell collection outcomes for multiple myeloma; mobilization matters in the era of IMiD induction","volume":"4","author":"Chandler","year":"2023","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2026.01.004_bib0008","doi-asserted-by":"crossref","first-page":"770.e1","DOI":"10.1016\/j.jtct.2021.06.016","article-title":"The efficacy and safety of chemotherapy-based stem cell mobilization in multiple myeloma patients who are poor responders to induction: the Mayo Clinic experience","volume":"27","author":"Vaxman","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.01.004_bib0009","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s12185-018-2408-4","article-title":"Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone","volume":"107","author":"Tanimura","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2026.01.004_bib0010","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbmt.2017.10.008","article-title":"Chemotherapy-based stem cell mobilization does not result in significant paraprotein reduction in myeloma patients in the era of novel induction regimens","volume":"24","author":"Oyekunle","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.01.004_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.08.006","article-title":"Efficacy of autologous stem cell transplantation for Myeloma patients with suboptimal response: a multicenter retrospective analysis","volume":"29","author":"Suzuki","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.01.004_bib0012","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.clml.2015.07.641","article-title":"Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation","volume":"15","author":"Kazmi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.01.004_bib0013","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.clml.2021.03.013","article-title":"KD-PACE salvage therapy for aggressive relapsed refractory multiple myeloma, plasma cell leukemia and extramedullary myeloma","volume":"21","author":"Alsouqi","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.01.004_bib0014","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.clml.2020.04.002","article-title":"KRD-PACE mobilization for multiple myeloma patients with significant residual disease before autologous stem-cell transplantation","volume":"20","author":"Cowan","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.01.004_bib0015","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2026.01.004_bib0016","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.01.004_bib0017","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging system for Multiple Myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.01.004_bib0018","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1182\/bloodadvances.2023011096","article-title":"Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS","volume":"7","author":"Guo","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.01.004_bib0019","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.01.004_bib0020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbmt.2013.11.003","article-title":"Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification","volume":"20","author":"Costa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.01.004_bib0021","doi-asserted-by":"crossref","first-page":"244.e241","DOI":"10.1016\/j.jtct.2020.12.009","article-title":"Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.01.004_bib0022","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bmt.2015.236","article-title":"A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma","volume":"51","author":"Silvennoinen","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.01.004_bib0023","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.clml.2026.01.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e20000","article-title":"Chemotherapy-based stem cell mobilization in multiple myeloma patients treated with novel agents: the Mayo Clinic experience","volume":"39","author":"Vaxman","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.01.004_bib0025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41409-024-02468-z","article-title":"Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial","volume":"60","author":"Jeker","year":"2025","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.clml.2026.01.004_bib0026","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2012.066","article-title":"New strategies for stem cell mobilization","volume":"4","author":"Lemoli","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2026.01.004_bib0027","first-page":"590.e591","article-title":"Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide \u00b1 plerixafor versus granulocyte colony-stimulating factor \u00b1 plerixafor in the lenalidomide era","volume":"27","author":"Johnsrud","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.01.004_bib0028","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12288-019-01108-7","article-title":"Impact of pre-transplant and post-transplant remission status of patients on survival in newly diagnosed multiple myeloma","volume":"35","author":"Ciftciler","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2026.01.004_bib0029","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.3324\/haematol.2015.128215","article-title":"Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen","volume":"101","author":"de Tute","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.01.004_bib0030","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2024014097","article-title":"MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma","volume":"9","author":"Chen","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.01.004_bib0031","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.01.004_bib0032","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12672-024-00891-8","article-title":"Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma","volume":"15","author":"Wang","year":"2024","journal-title":"Discov Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:19:10Z","timestamp":1776741550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265026000054"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Stem Cell Mobilization with Chemotherapy Versus G-CSF Alone for Multiple Myeloma Patients with Suboptimal Response Before Autologous Stem Cell Transplant","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}